Physician profile
Mark J Doerr
NPI 1477560738
$7,125.21
in general payments reported to CMS, 2019-2025
49 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $564 · 2021: $1,005 · 2022: $1,155 · 2023: $1,203 · 2024: $1,045 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,671.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,127.42 | 2019-2025 | Myrbetriq, Xtandi, Veozah |
| Abbvie INC. | $1,083.16 | 2019-2025 | Botox, Lupron Depot |
| Pfizer INC. | $623.78 | 2019-2025 | |
| 180 Medical, INC. | $504.81 | 2020-2025 | Gentlecath Glide, Gentlecath, Speedicath |
| Sumitomo Pharma America, INC. | $467.96 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $354.60 | 2019-2025 | Erleada |
| Merck Sharp & Dohme LLC | $301.21 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Tolmar Pharmaceuticals, INC. | $202.13 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $183.90 | 2019-2025 | Adstiladrin |
| Allergan, INC. | $169.88 | 2019-2022 | |
| Urogen Pharma, INC. | $158.18 | 2021-2024 | Jelmyto |
| Urovant Sciences INC | $157.64 | 2021-2022 | |
| Coloplast Corp | $152.36 | 2019-2023 | Speedicath |
| Endo Pharmaceuticals INC. | $150.65 | 2019-2023 | Edex, Aveed, Xiaflex |
| Dendreon Pharmaceuticals LLC | $113.62 | 2019-2024 | Provenge |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Doerr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.